13017-47-5

Basic information

• Product Name: (4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)hydrazine
• Synonyms: (4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)hydrazine;1-(4,6-DIMORPHOLINO-1,3,5-TRIAZIN-2-YL)HYDRAZINE;(2E)-2-hydrazinylidene-4,6-di(morpholin-4-yl)-1,2-dihydro-1,3,5-triazine
• CAS NO: 13017-47-5
• Molecular Formula: C₁₁H₁₉N₇O₂
• Molecular Weight: 281.31
• Mol File: 13017-47-5.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 546.6°Cat760mmHg
• Flash Point: 284.3°C
• Appearance: /
• Density: 1.39g/cm³
• Vapor Pressure: 5.32E-12mmHg at 25°C
• Refractive Index: 1.637
• CAS DataBase Reference: (4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)hydrazine(CAS DataBase Reference)
• NIST Chemistry Reference: (4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)hydrazine(13017-47-5)
• EPA Substance Registry System: (4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)hydrazine(13017-47-5)

Safety Data

• Hazardous Substances Data: 13017-47-5(Hazardous Substances Data)

Usage

Description

(4,6-Dimorpholin-4-yl-1,3,5-triazin-2-yl)hydrazine is a chemical compound that belongs to the class of hydrazine derivatives, featuring a triazine ring and two morpholine groups. (4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)hydrazine has garnered interest in the pharmaceutical and agricultural sectors due to its potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
(4,6-Dimorpholin-4-yl-1,3,5-triazin-2-yl)hydrazine is used as a potential drug candidate for the treatment of various diseases, including cancer and infectious diseases. Its unique chemical structure allows it to interact with specific biological targets, making it a promising candidate for further research and development.
Used in Agricultural Industry:
(4,6-Dimorpholin-4-yl-1,3,5-triazin-2-yl)hydrazine is used as a potential pesticide or herbicide due to its ability to inhibit the growth of certain organisms. Its effectiveness in controlling pests and unwanted plant growth could make it a valuable tool in the agricultural sector, provided further research confirms its safety and efficacy.
Further research is necessary to fully understand the potential uses and risks associated with (4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)hydrazine, as well as to optimize its application in both the pharmaceutical and agricultural industries.

InChI:InChI=1/C11H19N7O2/c12-16-9-13-10(17-1-5-19-6-2-17)15-11(14-9)18-3-7-20-8-4-18/h1-8,12H2,(H,13,14,15,16)

Upstream product

• 7597-22-0 2-chloro-4,6-di-morpholin-4-yl-[1,3,5]triazine 
• 6601-22-5 2,6-Dichloro-4-morpholino-1,3,5-triazine 

Downstream Products

• 65845-82-1 4-methoxy-benzaldehyde (4,6-di-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazone 
• 54807-20-4 benzoic acid N'-(4,6-di-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazide 
• 80751-31-1 [4-(4,6-Di-morpholin-4-yl-[1,3,5]triazin-2-ylazo)-3-methyl-phenyl]-dimethyl-amine 
• 91892-45-4 2,4-dimorpholino-6-(4-nitrobenzylidenehydrazino)-1,3,5-triazine 
• 80751-23-1 [4-(4,6-Di-morpholin-4-yl-[1,3,5]triazin-2-ylazo)-phenyl]-dimethyl-amine 
• 91892-44-3 2,4-dimorpholino-6-(2-nitrobenzylidenehydrazino)-1,3,5-triazine 
• 91892-61-4 5,7-dimorpholino-2-(2-nitrophenyl)<1,2,4>triazolo<1,5-a><1,3,5>triazine 
• 91892-52-3 5,8-dihydro-5-hydroxy-5,7-dimorpholino-3-(2-nitrophenyl)-1,2,4-triazolo<4,3-a><1,3,5>triazine 
• 91892-53-4 5,8-dihydro-5-hydroxy-5,7-dimorpholino-3-(4-nitrophenyl)-1,2,4-triazolo<4,3-a><1,3,5>triazine 
• 65845-89-8 3-(4-methoxy-phenyl)-5,7-di-morpholin-4-yl-[1,2,4]triazolo[4,3-a][1,3,5]triazine 
• 66048-75-7 2-(4-methoxy-phenyl)-5,7-di-morpholin-4-yl-[1,2,4]triazolo[1,5-a][1,3,5]triazine 
• 908141-08-2 C₁₈H₂₃N₇O₅ 
• 1160617-06-0 C₂₇H₂₉N₇O₃ 
• 331647-67-7 C₂₁H₂₉N₇O₅ 

Relevant articles and documents

Antitubercular Triazines: Optimization and Intrabacterial Metabolism

The triazine antitubercular JSF-2019 was of interest due to its in vitro efficacy and the nitro group shared with the clinically relevant delamanid and pretomanid. JSF-2019 undergoes activation requiring F420H2 and one or more nitroreductases in addition to Ddn. An intrabacterial drug metabolism (IBDM) platform was leveraged to demonstrate the system kinetics, evidencing formation of NO? and a des-nitro metabolite. Structure-activity relationship studies focused on improving the solubility and mouse pharmacokinetic profile of JSF-2019 and culminated in JSF-2513, relying on the key introduction of a morpholine. Mechanistic studies with JSF-2019, JSF-2513, and other triazines stressed the significance of achieving potent in vitro efficacy via release of intrabacterial NO? along with inhibition of InhA and, more generally, the FAS-II pathway. This study highlights the importance of probing IBDM and its potential to clarify mechanism of action, which in this case is a combination of NO? release and InhA inhibition. Wang et al. disclose the optimization of a triazine antitubercular agent and probe its mechanism of action. They demonstrate the significance of studying intrabacterial drug metabolism. Through this approach and other methods, they evidence a novel mechanism involving NO? release and inhibition of the cell wall biosynthesis enzyme InhA.

Synthesis, X-ray crystal structures, and preliminary antiproliferative activities of new s-triazine-hydroxybenzylidene hydrazone derivatives

We herein report a new small library of Schiff-base compounds that encompasses s-triazine and (2 or 4)-hydroxylbenzylidene derivatives. These compounds were synthesized through a hydrazone linkage connecting both the s-triazine and hydroxybenzylidene deri

Synthesis, Characterization, and Tautomerism of 1,3-Dimethyl Pyrimidine-2,4,6-Trione s-Triazinyl Hydrazine/Hydrazone Derivatives

1,3,5-Triazines and pyrimidine-2,4,6-triones belong to that class of compounds which are well known in literature for possessing wide range of biological activities. Here, we report a new family of compounds that encompasses these two structures. The unio

Design and synthesis of mono-and di-pyrazolyl-s-triazine derivatives, their anticancer profile in human cancer cell lines, and in vivo toxicity in zebrafish embryos

s-Triazine is considered a privileged structure, as it is found in several FDA-approved drugs. In the framework of our ongoing medicinal chemistry project based on the use of s-triazine as a scaffold, we synthesized a series of mono- and di-pyrazolyl-s-triazine derivatives and tested them against four human cancer cell lines, namely Human breast carcinoma (MCF 7 and MDA-MB-231), hepatocellular carcinoma (HepG2), colorectal carcinoma (LoVo), and leukemia (K562). The cell viability assay revealed that most of the s-triazine compounds induced cytotoxicity in all four types of human cancer cell lines, however, compounds 4a, and 6g, both of them have a piperidine moiety in their structure were most effective. These two compounds affected the cell viability of cancer cells, with IC50 values within the range between 5 to 9 μM. The cell cycle analysis showed that 4a and 6g induced S and G2/M phase cell cycle arrest in K562 cells. This could be the mechanism by which these molecules induced cytotoxicity in tested cancer cells. The prepared compounds were tested in zebrafish embryos to evaluate in vivo and developmental toxicity of the pyrazolyl-s-triazine derivatives in animals. None of the derivatives were lethal in the concentration range tested.